Adherium (ASX:ADR) share price rockets 53% on US FDA clearance

The company's shares are hitting a new 6-month high…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Adherium Ltd (ASX: ADR) share price soared to dizzying heights today. This comes after the digital healthcare company announced it has received a 510(k) clearance from the United States Food and Drug Administration (FDA).

At the end of Thursday's market close, Adherium shares finished up 53.33% to 2.3 cents.

A drawing of a white rocket streaking up, indicating a surging share pirce movement

Image source: Getty Images

Milestone achievement for Adherium

The Adherium share price surged today as investors were fighting to get a hold of the company's shares.

According to its release, Adherium advised that the United States FDA has cleared the pathway for the company to begin commercialisation for Hailie Sensor.

The company's next generation, Hailie Sensor are devices that attach to a patient's Asthma or Chronic Obstructive Pulmonary Disease (COPD) medication inhaler. This allows caregivers to monitor medication use and capture clinical data whilst supporting the patient's management and treatment journey.

Furthermore, the latest Hailie Sensor is designed for use with AstraZeneca's Symbicort aerosol inhaler.

The total addressable market for treating Asthma and COPD patients in the United States is estimated to be around US$1.5 billion.

With the Hailie Sensor approved, this means that the FDA has granted 10 510(k) licences to Adherium for its devices. As such, the company has become a market leader in respiratory digital health.

Adherium stated that it intends to pursue multiple channels in order for Hailie Sensor to enter the market.

Adherium CEO, Rick Legleiter commented:

The FDA's first clearance of our next generation Hailie sensors with physiological measures is a significant regulatory step for the business.

The stage is now set for physiological measures to be coupled with our existing adherence sensor capability giving us the total 'one-two punch' to deliver the best value proposition of any smart inhaler digital solution in the world.

…Adherium will expand its addressable respiratory medication market coverage and establish a preeminent business partnering position for providers, payors and digital health affiliates.

About the Adherium share price

Since this time last year, Adherium shares were mostly tracking lower until today, currently down 22%. Year-to-date, its shares are also in negative territory, down 14%.

Adherium presides a market capitalisation of roughly $54.3 million and has 2.1 billion shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
ASX Share Market News

ASX 200 technology and healthcare shares continued their comeback last week

ASX 200 tech stocks rose 8.2% and healthcare increased 5.5% over the week.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Male doctor in a lab coat working at laptop looking serious.
Broker Notes

Buy, hold, sell: What is Bell Potter saying about CSL shares?

Bell Potter has been looking at the biotech giant ahead of its results release.

Read more »

A bored woman looking at her computer, it's bad news.
Share Fallers

These were the worst-performing ASX 200 shares in July

These shares had a tough time in July. Let's find out why.

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Buy, hold, sell: Newmont, Rio Tinto, and Santos shares

Morgans has updated its view on these mining shares.

Read more »

Happy work colleagues give each other a fist pump.
Share Gainers

These were the best-performing ASX 200 shares in July

These shares had a month to remember. Let's find out why.

Read more »

Male investor holds a magnifying glass to his eye.
Broker Notes

Brokers name 3 ASX shares to buy in August

Three broker buy ratings worth a closer look this month.

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX scraped a win this Friday to close the week.

Read more »